Biomea Fusion Inc (BMEA)
$7.08
Performance
- $6.96$7.72$7.08
1.69%
Downside
Day's Volatility :9.84%
Upside
8.29%
- $3.61$22.74$7.08
49.01%
Downside
52 Weeks Volatility :84.12%
Upside
68.87%
Returns
| Period | Biomea Fusion Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 71.01% | 5.1% | 0.0% |
6 Months | -55.47% | 4.9% | 0.0% |
1 Year | -58.01% | 16.6% | 0.0% |
3 Years | -47.24% | 13.2% | -22.3% |
Highlights
Market Capitalization | 256.4M |
Book Value | $2.87 |
Earnings Per Share (EPS) | -3.9 |
Wall Street Target Price | 22.57 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -48.2% |
Return On Equity TTM | -85.09% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -146.7M |
Diluted Eps TTM | -3.9 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.96 |
EPS Estimate Next Year | -3.42 |
EPS Estimate Current Quarter | -1.07 |
EPS Estimate Next Quarter | -1.03 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 218.79%
Technicals Summary
Sell
Neutral
Buy
Biomea Fusion Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Biomea Fusion Inc | 22.7% | -55.47% | -58.01% | -47.24% | -61.94% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Biomea Fusion Inc | NA | NA | NA | -3.96 | -0.85 | -0.48 | NA | 2.87 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Biomea Fusion Inc | Buy | $256.4M | -61.94% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Biomea Fusion Inc
Vs REGN
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 95.1%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 116.4%
Institutional Holdings
FMR Inc
14.89%State Street Corporation
12.39%Cormorant Asset Management, LLC
9.86%BlackRock Inc
6.48%Baker Bros Advisors LP
5.82%Vanguard Group Inc
3.84%
Company Information
biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro
Organization | Biomea Fusion Inc |
Employees | 112 |
CEO | Mr. Thomas Andrew Butler |
Industry | Healthcare |
